Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.32 - $9.10
Previous CloseN/A
Volume547.29K
Average Volume (3M)2.53M
Market Cap
$475.74M
Enterprise Value$227.65M
Total Cash (Recent Filing)$164.32M
Total Debt (Recent Filing)$75.32M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Oct 30, 2025EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding61,545,270
10 Day Avg. Volume3,138,593
30 Day Avg. Volume2,534,215
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue-29.04
Enterprise Value/Gross Profit-26.97
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$15.67Price Target Upside90.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
EarningsVerastem reported revenues of $2.1M for the quarter, higher than consensus estimate of $1.0M, and a net loss of $0.35 per diluted share, compared to consensus estimated net loss of $0.73 per share.
Market PotentialThe company's KRASG12D inhibitor program presents a significant market opportunity, estimated at over $1.5 billion.
Regulatory ApprovalVerastem’s avutometinib plus defactinib combination received accelerated approval from the FDA for the treatment of low-grade serous ovarian cancer.
Bears Say
Regulatory ChallengesManagement is in discussion with the EU agency to clarify regulatory requirements, believing robust reimbursement will likely need Phase 3 study results.
Safety ConcernsSafety, especially gastrointestinal signals, remains a key focus due to high rates of grade 3 or higher treatment-related adverse effects.
Verastem News
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $2.32 and its highest was $9.10 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $475.74M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Oct 30, 2025 which is in 74 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Aug 07, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.728 by $0.338.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.6.
How many shares outstanding does Verastem have?
Verastem has 61,545,270 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.728. Following the earnings report the stock price went up 19.929%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
Verastem Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (90.63% Upside)
$15.67 (90.63% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 62.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $694.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
252.78%
12-Months-Change
Fundamentals
Return on Equity
-437.92%
Trailing 12-Months
Asset Growth
85.60%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc. (VSTM) is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life for cancer patients. The company primarily operates in the oncology sector, with a strong emphasis on targeting malignant cells and the tumor microenvironment. Its core products and services revolve around innovative therapies for cancer treatment, particularly targeting specific pathways involved in cancer cell proliferation and survival.
VSTM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant achievements, including an early FDA approval and successful product launch, strong initial market penetration, and financial strength. Despite increased R&D and SG&A expenses, the positive momentum and strategic execution in the commercial launch phase suggest a positive outlook.View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
$15.67
▲(90.63% Upside)
Technical Analysis
Rigel
―
Astria Therapeutics
―
Personalis
―
Aura Biosciences Inc
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
1.40% Insiders
5.75% Mutual Funds
47.31% Other Institutional Investors
34.24% Public Companies and
Individual Investors